Glucorticoid Taper Regimen ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
40高安動脈炎2

40. 高安動脈炎


臨床試験数 : 24 薬物数 : 40 - (DrugBank : 18) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 110
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2061210007
13/10/202128/05/2021A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis Takayasu ArteritisUstekinumab
Participants will receive IV infusion and SC injection of ustekinumab.

Placebo
Participants will receive IV infusion and SC injection of matching placebo.

Glucorticoid Taper Regimen
Glucocorticoid will be administered orally.
Nishikawa KazukoNULLRecruiting>= 18age old<= 75age oldBoth50Phase 3Japan
2NCT04882072
(ClinicalTrials.gov)
September 15, 202110/5/2021A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu ArteritisTakayasu ArteritisDrug: Ustekinumab;Other: Placebo;Drug: Glucorticoid Taper RegimenJanssen Pharmaceutical K.K.NULLActive, not recruiting15 Years75 YearsAll14Phase 3Japan